Literature DB >> 16977650

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.

Lei Huo1, Nour Sneige, Kelly K Hunt, Constance T Albarracin, Adriana Lopez, Erika Resetkova.   

Abstract

BACKGROUND: Among patients with core-needle biopsy (CNB)-diagnosed ductal carcinoma in situ (DCIS), the guidelines for the selection of patients to undergo sentinel lymph node (SLN) biopsy are not well defined, and many patients with no invasion undergo an unnecessary SLN biopsy. The objective of this study was to identify the predictors of invasion in patients with CNB-diagnosed DCIS and, thus, to help determine the most appropriate candidates for SLN biopsy.
METHODS: The authors retrospectively evaluated 200 consecutive patients with CNB-diagnosed DCIS who underwent final excision at their institution between May 1, 2002 and June 30, 2005. Demographic data, the size and type of lesion on imaging studies, histologic features of DCIS on CNB, the number of cores taken, and the number of cores involved by DCIS were correlated with invasion on excision and SLN biopsy outcome.
RESULTS: Forty-one of 200 patients (21%) had invasive carcinoma diagnosed on final excision. Parameters that correlated with invasion were a mass lesion, lesion size >1.5 cm, high nuclear grade, and the presence of lobular cancerization on CNB. A multivariate logistic regression model was developed to predict invasion. At the time of breast surgery, 103 of 200 patients (52%) underwent SLN biopsy, and 34 had invasion diagnosed on final excision. Three patients had 1 positive SLN each.
CONCLUSIONS: A mass lesion, lesion size >1.5 cm, and the presence of lobular cancerization on CNB were significant, independent predictors of invasion in patients with DCIS. The authors recommended the inclusion of these predictors in the guidelines for selecting patients for SLN biopsy to reduce the number of unnecessary procedures. 2006 American Cancer Society

Entities:  

Mesh:

Year:  2006        PMID: 16977650     DOI: 10.1002/cncr.22216

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

2.  Detection of invasive components in cases of breast ductal carcinoma in situ on biopsy by using apparent diffusion coefficient MR parameters.

Authors:  Naoko Mori; Hideki Ota; Shunji Mugikura; Chiaki Takasawa; Junya Tominaga; Takanori Ishida; Mika Watanabe; Kei Takase; Shoki Takahashi
Journal:  Eur Radiol       Date:  2013-06-04       Impact factor: 5.315

3.  Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.

Authors:  Hai-Jeon Yoon; Yemi Kim; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2015-06-11       Impact factor: 5.315

4.  The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy.

Authors:  Mariko Goto; Sachiko Yuen; Kentaro Akazawa; Kaori Nishida; Eiichi Konishi; Mariko Kajihara; Nobuhiko Shinkura; Kei Yamada
Journal:  Eur Radiol       Date:  2011-12-30       Impact factor: 5.315

5.  Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences.

Authors:  Xiao Sun; Hao Li; Yan-Bing Liu; Zheng-Bo Zhou; Peng Chen; Tong Zhao; Chun-Jian Wang; Zhao-Peng Zhang; Peng-Fei Qiu; Yong-Sheng Wang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

6.  Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?

Authors:  Melissa Pilewskie; Michelle Stempel; Hope Rosenfeld; Anne Eaton; Kimberly J Van Zee; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2016-05-12       Impact factor: 5.344

7.  Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

Authors:  Melissa Pilewskie; Maria Karsten; Julia Radosa; Anne Eaton; Tari A King
Journal:  Ann Surg Oncol       Date:  2016-03-09       Impact factor: 5.344

Review 8.  The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Tatyana Shamliyan; Beth A Virnig; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

9.  Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification.

Authors:  Sara M Bundred; Anthony J Maxwell; Julie Morris; Yit Y Lim; Md Janick Harake; Sigrid Whiteside; Nigel J Bundred
Journal:  Br J Radiol       Date:  2015-12-14       Impact factor: 3.039

10.  HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.

Authors:  Robert E Roses; E Carter Paulson; Anupama Sharma; Jeanne E Schueller; Harvey Nisenbaum; Susan Weinstein; Kevin R Fox; Paul J Zhang; Brian J Czerniecki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.